Fluticasone propionate/salmeterol (Advair HFA) vs Salbutamol HFA-152a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 471 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs) During Run-in Period" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: April 2027 · NCT06433921 (registry estimate)
Reported efficacy
Number of participants with Adverse Events (AEs) (Up to 3 months): Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). (not_applicable)
Result source: NCT06261957
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fluticasone propionate/salmeterol (Advair HFA) | Salbutamol HFA-152a |
|---|---|---|
| Severe exacerbations, annualised rate | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 | —Not reported |
| Trough FEV1, change | —Not posted · NCT00646620 | —Not reported |
| ACQ-5, change | —Not posted · NCT00646620 | —Not reported |
| OCS dose reduction | —Not posted · NCT00646620 | —Not reported |
Severe exacerbations, annualised rate
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
- Salbutamol HFA-152a
- —Not reported
Trough FEV1, change
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Salbutamol HFA-152a
- —Not reported
ACQ-5, change
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Salbutamol HFA-152a
- —Not reported
OCS dose reduction
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Salbutamol HFA-152a
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fluticasone propionate/salmeterol (Advair HFA): 4 of 4 rows · Salbutamol HFA-152a: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone propionate/salmeterol (Advair HFA) | Salbutamol HFA-152a |
|---|---|---|
| Dropout rate | —50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence | —800 ugb NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result—200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence | —800 ugb NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result—200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence | 0%800 ugb NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result3.3%200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 50/100 mcg/daya upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence | 800 ugb catheter site related reaction 30% headache 16.7% cough 10% NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result200 ug catheter site haematoma 16.7% headache 10% abdominal pain 6.7% NCT06433908 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone propionate/salmeterol (Advair HFA)
+ 12 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · Salbutamol HFA-152a's landscape